Chemo, radiation, and immunotherapy for lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of platinum-based chemotherapy, large fractionated radiotherapy, and the immunotherapy drug tislelizumab for people with stage IIIB to IV non-squamous non-small cell lung cancer. It aims to see if this approach can help control the cancer without certain gene mutations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stage IIIB, IIIC, or IV non-squamous non-small cell lung cancer.
- Your tumor does not have certain gene changes (like EGFR, ALK, BRAF, ROS1, RET, MET) or targeted therapy has stopped working.
- You are able to take care of yourself (ECOG score 0-2).
- You have not had chemotherapy or other cancer treatment that ended less than 3 months before the cancer came back.
- You do not have uncontrolled autoimmune disease or a recent severe autoimmune reaction.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
This trial tests a combination of tislelizumab (an immunotherapy drug) with chemotherapy for people with a type of lung cancer that has not spread to other organs and cannot be removed with surgery. The goal is to see if this treatment can shrink tumors and help people live longer.
This trial tests a combination of chemotherapy, radiation, and two targeted drugs (surufatinib and tislelizumab) for people with stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this approach works better than standard treatment.
This trial combines an immunotherapy drug (tislelizumab) with chemotherapy before surgery to try to shrink the tumor and possibly make surgery possible later. The goal is to improve outcomes for people with stage III non-small cell lung cancer that is not removable at diagnosis.
This trial tests combining the drug tislelizumab with chemotherapy for people with stage III non-small cell lung cancer that hasn't been treated yet. It aims to see if this combination can shrink or control the cancer better.
This trial tests a new schedule of chemo-radiation (fewer, stronger sessions) followed by an immunotherapy drug called tislelizumab. The goal is to see if this approach works better than the standard longer schedule for people with stage III lung cancer that can't be surgically removed.
Hear when a new Tislelizumab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.